FC(F)(F)C(O)=O.[Cl:8][C:9]1[N:10]=[C:11]([N:18]2[CH2:23][CH2:22][O:21][CH2:20][CH2:19]2)[C:12]2[CH2:17][NH:16][CH2:15][C:13]=2[N:14]=1.C(O)(C(F)(F)F)=O.C(N(CC)CC)C.Cl[C:39]([O:41][CH2:42][CH3:43])=[O:40]>CN(C=O)C>[Cl:8][C:9]1[N:10]=[C:11]([N:18]2[CH2:19][CH2:20][O:21][CH2:22][CH2:23]2)[C:12]2[CH2:17][N:16]([C:39]([O:41][CH2:42][CH3:43])=[O:40])[CH2:15][C:13]=2[N:14]=1
To a stirred solution of 4-(2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)morpholine trifluoroacetate (intermediate 20) as a TFA salt (708 mg, 2.0 mmol) in anhydrous DMF (5 ml) was added triethylamine (5550, 4.0 mmol) and the reaction was stirred at RT for two hours. After this time, ethyl chloroformate (228 μl, 2.4 mmol) was added dropwise and the reaction was stirred at RT overnight. The reaction was partitioned between water and ethyl acetate and the aqueous phase was extracted into ethyl acetate. The organic extracts were combined, washed with brine, dried over magnesium sulphate and concentrated in vacuo to afford the title compound which was used without further purification.
読み込み中…
